Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 12, 2012, Pages

  Martí Carvajal, Arturo J ^a   Solà, Ivan ^b   Gluud, Christian ^c   Lathyris, Dimitrios ^d   Anand, Vidhu ^e  

^a Iberoamerican Cochrane Network   (Venezuela)

^b BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^c Rigshospitalet   (Denmark)

^d General Hospital "G Gennimatas"   (Greece)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DROTRECOGIN; PROTEIN C; RECOMBINANT PROTEIN;

ADULT; AGE; CAUSE OF DEATH; CHILD; DRUG RECALL; EARLY TERMINATION OF CLINICAL TRIAL; HUMAN; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SEPTIC SHOCK;

ADULT; AGE FACTORS; ANTI-INFECTIVE AGENTS; CAUSE OF DEATH; CHILD; DRUG RECALLS; EARLY TERMINATION OF CLINICAL TRIALS; HOSPITAL MORTALITY; HUMANS; PROTEIN C; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; SEPSIS; SHOCK, SEPTIC;

EID: 84874131345     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004388.pub6     Document Type: Article

References (196)

1. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. New England Journal of Medicine 2005;353(13):1332-41. [MEDLINE: 16192478]x-wiley/crsRef/3118424
2. Laterre PF, Abraham E, Janes JM, Trzaskoma BL, Correl NL, Booth F. ADDRESS (ADministration of DRotrecogin alfa[activated] in Early stage Severe sepsis) long-term follow-up: one year safety and efficacy evaluation. Critical Care Medicine 2007;35(6):1457-63. [MEDLINE: 17452935]x-wiley/crsRef/3118425
3. Annane D, Timsit JF, Megarbane B, Martin C, Misset B, Mourvillier B, et al. Recombinant human activated protein C for adults with septic shock: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine 2013; Vol. Mar 22, issue Epub ahead of print. [PUBMED: 23525934]x-wiley/crsRef/3118427
4. Dhainaut JF, Antonelli M, Wright P, Desachy A, Reignier J, Lavoue S, et al. Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock. Intensive Care Medicine 2009;35(7):1187-95. [MEDLINE: 19263034]x-wiley/crsRef/3118429
5. Angus DC, Laterre OF, Helterbrand J, Ely EW, Ball DE, Garg R, et al. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Critical Care Medicine 2004;32(11):2199-206. [MEDLINE: 15640631]x-wiley/crsRef/3118431
6. Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Critical Care Medicine 2003;31(1):1-11. [MEDLINE: 12544986]x-wiley/crsRef/3118432
7. Barie PS, Williams MD, McCollam JS, Bates BM, Qualy RL, Lowry SF, et al. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. American Journal of Surgery 2004;188(3):212-20. [MEDLINE: 15450822]x-wiley/crsRef/3118433
8. Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Critical Care 2003;7(2):155-63. [MEDLINE: 12720562]x-wiley/crsRef/3118434
9. Bernard GR, Margolis BD, Shanies HM, Ely EW, Wheeler AP, Levy H, et al. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 2004;125(6):2206-16. [MEDLINE: 15189943]x-wiley/crsRef/3118435
10. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. New England Journal Medicine 2001;344(10):699-709. [MEDLINE: 11236773]x-wiley/crsRef/3118436
11. Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Medicine 2003;29(6):894-903. [MEDLINE: 12712239]x-wiley/crsRef/3118437
12. Dhainaut JF, Laterre PF, LaRosa SP, Levy H, Garber GE, Heiselman D, et al. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Critical Care Medicine 2003;31(9):2291-301. [MEDLINE: 14501959]x-wiley/crsRef/3118438
13. Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson B, Brandt JT, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis 2004;11:1924-33. [MEDLINE: 15550023]x-wiley/crsRef/3118439
14. Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, et al. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thrombosis and Haemostasis 2003;90(4):642-53. [MEDLINE: 14515185]x-wiley/crsRef/3118440
15. Ely EW, Angus DC, Williams MD, Bates B, Qualy R, Bernard GR. Drotrecogin alfa (activated) treatment of older patients with severe sepsis. Clinical Infectious Disease 2003;37(2):187-95. [MEDLINE: 12856210]x-wiley/crsRef/3118441
16. Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Critical Care Medicine 2003;31(1):12-9. [MEDLINE: 1254498]x-wiley/crsRef/3118442
17. FDA 2001a. Food and Drug Administration. FDA Anti-Infective Drugs Advisory Committee12 September 2001: Briefing Document for XIGRIS for the Treatment of Severe Sepsis. Eli Lilly and Company. 06 August 2001. Available for public disclosure without redaction. Accessed online June 10, 2009. http://www.fda.gov/ohrms/dockets/AC/01/briefing/3797b1_01_Sponsor.pdf 2001. x-wiley/crsRef/3118443
18. FDA 2001b. FDA Briefing document: Anti-infective Advisory Committee. Drotrecogin alfa (activated). [Recombinant human activated protein (rhAPC)]. XIGRIS™ BLA # 125029/0. September 12. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1_02_FDAbriefing.pdf 2001. x-wiley/crsRef/3118444
19. FDA 2005. 2005 Safety Alert: Xigris [drotrecogin alfa (activated)]. http://www.fda.gov/medwatch/safety/2005/xigris_DHCP.htm. Accessed online May 28, 2006. x-wiley/crsRef/3118445
20. Fry DE, Beilman G, Johnson S, Williams MD, Rodman G, Booth FV, et al. Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis. Surgical Infections 2004;5:253-9. [MEDLINE: 15684796]x-wiley/crsRef/3118446
21. Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Critical Care Medicine 2005;33:952-61. [MEDLINE: 15891319]x-wiley/crsRef/3118447
22. Laterre PF, Levy H, Clermont G, Ball DE, Garg R, Nelson DR, et al. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Critical Care Medicine 2004;11:2207-18. [MEDLINE: 15640632]x-wiley/crsRef/3118448
23. Laterre PF, Nelson DR, Macias W, Abraham E, Sashegyi A, Williams MD. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety. Journal of Critical Care 2007;22(2):142-52. [ISSN: 0883-9441]x-wiley/crsRef/3118449
24. Macias WL, Dhainaut JF, Yan SC, Helterbrand JD, Seger M, Johnson G3rd, et al. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clinical Pharmacology and Therapeutics 2002;72(4):391-402. [MEDLINE: 2386641]x-wiley/crsRef/3118450
25. Macias WL, Nelson DR. Severe protein C deficiency predicts early death in severe sepsis. Critical Care Medicine 2004;32(5 Suppl):223-8. [MEDLINE: 15118522]x-wiley/crsRef/3118451
26. Morris P, Kalil A, Schein R. Drotrecogin alfa (activated) improved survival in patients with severe sepsis on mechanical ventilation: results from the PROWESS trial [abstract]. American Journal of Respiratory and Critical Care Medicine 2002;165(8 Suppl):A470. x-wiley/crsRef/3118452
27. Opal SM, Garber GE, LaRosa SP, Maki DG, Freebairn RC, Kinasewitz GT, et al. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clinical Infectious Disease 2003;37(1):50-8. [MEDLINE: 12830408]x-wiley/crsRef/3118453
28. Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, et al. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: Analysis of efficacy and safety data in a large surgical cohort. Surgery 2006;140(5):726-39. [MEDLINE: 17084715]x-wiley/crsRef/3118454
29. Schein R, Kalil A, Sollet JP. Drotrecogin alfa (activated) reduces mortality in chronic obstructive pulmonary disease patients with severe sepsis. Results from the PROWESS trial [abstract]. American Journal of Respiratory and Critical Care Medicine 2002;165:23. x-wiley/crsRef/3118455
30. Shaw AD, Vail GM, Haney DJ, Xie J, Williams MD. Severe protein C deficiency is associated with organ dysfunction in patients with severe sepsis. Journal of Critical Care 2011;26(6):539-45. [PUBMED: 21737232]x-wiley/crsRef/3118456
31. Shorr AF, Bernard GR, Dhainaut JF, Russell JR, Macias WL, Nelson DR, et al. Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Critical Care 2006;10(3):R92. [MEDLINE: 16780598]x-wiley/crsRef/3118457
32. Shorr AF, Nelson DR, Wyncoll DL, Reinhart K, Brunkhorst F, Vail GM, et al. Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated). Critical Care (London, England) 2008;12(2):R45. [MEDLINE: 18394162]x-wiley/crsRef/3118458
33. Vail GM. Biomarkers of thrombosis, fibrinolysis, and inflammation in patients with severe sepsis due to community-acquired pneumonia with and without streptococcus pneumoniae. Infection 2009;37(4):358-64. [PREV200900533209]x-wiley/crsRef/3118459
34. Vincent JL. Drotrecogin alfa (activated) in the treatment of severe sepsis. Current Drug Safety 2007;2(3):227-31. [MEDLINE: 18690972]x-wiley/crsRef/3118461
35. Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Critical Care Medicine 2003;31(3):834-40. [MEDLINE: 12626993]x-wiley/crsRef/3118460
36. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al. Drotrecogin alfa (activated) in adults with septic shock. The New England Journal of Medicine 2012;366(22):2055-64. [PUBMED: 22616830]x-wiley/crsRef/3118463
37. Ranieri VM, Thompson BT, Finfer S, Barie PS, Dhainaut JF, Douglas IS, et al. Unblinding plan of PROWESS-SHOCK trial. Intensive Care Medicine 2011; Vol. 37, issue 8:1384-5. [PUBMED: 21691888]x-wiley/crsRef/3118464
38. Thompson BT, Ranieri VM, Finfer S, Barie PS, Dhainaut JF, Douglas IS, et al. Statistical analysis plan of PROWESS SHOCK study. Intensive Care Medicine 2010; Vol. 36, issue 11:1972-3. [PUBMED: 20689934]x-wiley/crsRef/3118465
39. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007;369(9564):836-43. [MEDLINE: 17350452]x-wiley/crsRef/3118467
40. Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE Jr, Russell JA, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Critical Care Medicine 2001;29(11):2051-9. [MEDLINE: 11700394]x-wiley/crsRef/3118469
41. Alaniz C. An update on activated protein C (Xigris) in the management of sepsis. P & T 2010; Vol. 35, issue 9:504-29. [PUBMED: 20975809]x-wiley/crsRef/3118471
42. Barie PS, Hydo LJ, Shou J, Eachempati SR. Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome. Surgical Infections. United States, 2011; Vol. 12, issue 6:443-9. [PUBMED: 22185191]x-wiley/crsRef/3118473
43. Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen Cawley R, et al. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics 2004;113(1 Pt 1):7-17. [MEDLINE: 14702440]x-wiley/crsRef/3118475
44. Bearden DT, Garvin CG. Recombinant human activated protein C for use in severe sepsis. Annals of Pharmacotherapy 2002;36(2):1424-9. [ISSN: 1060-0280]x-wiley/crsRef/3118477
45. Bernard GR, Margolis BD, Shanies HM, Ely EW, Wheeler AP, Levy H, et al. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 2004;125(6):2206-16. [MEDLINE: 15189943]x-wiley/crsRef/3118479
46. Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D. Use of drotrecogin alfa (activated) in Italian intensive care units: The results of a nationwide survey. Intensive Care Medicine 2007;33(3):426-34. [MEDLINE: 17325836]x-wiley/crsRef/3118481
47. Boyle A, McKenzie C, Yassin S, McLuckie A, Wyncoll D. Adverse events and clinical outcome associated with drotrecogin alfa-activated: A single-center experience of 498 patients over 8 years. Journal of Critical Care 2012; Vol. 27, issue 3:320.e7-320.e12. [PUBMED: 22172792]x-wiley/crsRef/3118483
48. Casey M. Recombinant activated protein C (drotecogin alfa) in severe sepsis [Drotrecogin Alfa Activado (Proteína C activada recombinante) identificación de paciente e indicaciones para el tratamiento de la sepsis severa con alto riesgo de muerte]. Hematología (Buenos Aires) 2002;6:42-6. x-wiley/crsRef/3118485
49. Costa V, Brophy JM. Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis. BMC Anesthesiology 2007;7(5):1-11. [MEDLINE: 17592639]x-wiley/crsRef/3118487
50. Decruyenaere J, De Backer D, Spapen H, Laterre PF, Raemaekers J, Rogiers P, et al. 90-day follow-up of patients treated with drotrecogin alfa (activated) for severe sepsis: a Belgian open label study. Acta Clinica Belgica 2009;64(1):16-22. [MEDLINE: 19317237]x-wiley/crsRef/3118489
51. Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, et al. Effectiveness of treatments for severe sepsis: A prospective multicenter observational study. American Journal of Respiratory and Critical Care Medicine 2009;180(9):861-6. [MEDLINE: 19696442]x-wiley/crsRef/3118491
52. Freeman BD, Zehnbauer BA, Buchman TG. A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis. Shock 2003;20(1):5-9. [MEDLINE: 12813361]x-wiley/crsRef/3118493
53. Goldstein B, Nadel S, Peters M, Barton R, Machado F, Levy H, et al. Enhance: Results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis. Pediatric Critical Care Medicine 2006;7(3):200-11. [MEDLINE: 16575354]x-wiley/crsRef/3118495
54. Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, et al. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris(R)) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. Health Technology Assessment 2005;140:1-126. [MEDLINE: 15774234]x-wiley/crsRef/3118497
55. Heslet L, Nielsen JD, Schierbeck J, Andersen JS. Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis. Ugeskrift for Laeger 2004;166(11):997-1002. [MEDLINE: 15049234]x-wiley/crsRef/3118499
56. Houston G, Cuthbertson BH. Activated protein C for the treatment of severe sepsis. Clinical Microbiology and Infection 2009;5(4):319-24. [MEDLINE: 19416303]x-wiley/crsRef/3118501
57. Kalil A, La Rosa S. Real-life experience with drotrecogin alfa activated for severe sepsis: An effectiveness and safety meta-analysis. Critical Care Medicine 2010;38:A117. x-wiley/crsRef/3118503
58. Kanji S, Perreault MM, Chant C, Williamson D, Burry L. Evaluating the use of drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. Intensive Care Medicine 2007;33(3):517-33. [MEDLINE: 17325837]x-wiley/crsRef/3118505
59. Khan A, Agarwal R, Aggarwal AN, Gupta D. Prevalence of serious bleeding events and intracranial hemorrhage in patients receiving activated protein C: A systematic review and meta-analysis. Respiratory Care 2010;55(7):901-10. [PUBMED: 20587103]x-wiley/crsRef/3118507
60. Kylat Ranjit I, Ohlsson A. Recombinant human activated protein C for severe sepsis in neonates. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2012, issue 4. [DOI: 10.1002/14651858.CD005385.pub3; CD005385]x-wiley/crsRef/3118509
61. Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, et al. Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). American Journal of Respiratory and Critical Care Medicine 2007;176(5):483-90. [MEDLINE: 17556722]x-wiley/crsRef/3118511
62. Lopez Sanchez F, Mas-Serrano P, Caturla Such J, Mignini M, Navarro J. Drotrecogin alfa (activated) in real-life clinical practice for management of severe sepsis in surgical patients. Intensive Care Medicine 2010;36:S193. x-wiley/crsRef/3118513
63. Lucioni C, Mazzi S, Christopher C. The treatment of patients with severe sepsis using drotrecogin alfa: an economic evaluation for Italy [Il trattamento di pazienti con sepsi grave mediante drotrecogin alfa: una valutazione economica con riferimento allItalia]. Farmeconomia e Percorsi Terapeutici 2002;3(3):171-7. x-wiley/crsRef/3118515
64. Marraro GA. Treatment of septic shock and use of drotrecogin alfa (activated) in children. Expert Review of Anti-Infective Therapy 2009;7(7):769-72. [EMBASE: 2009575232]x-wiley/crsRef/3118517
65. McCoy C, Matthews SJ. Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis. Clinical Therapeutics 2003;25(2):396-421. [MEDLINE: 12749504]x-wiley/crsRef/3118519
66. McCoy C. Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis. Expert Opinion on Drug Safety 2004;3(6):625-37. [MEDLINE: 15500421]x-wiley/crsRef/3118521
67. Neilson AR, Burchardi H, Chinn C, Clouth J, Schneider H, Angus D. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany. Journal of Critical Care 2003;18(4):217-27. [MEDLINE: 14691895]x-wiley/crsRef/3118523
68. Sadique MZ, Grieve R, Harrison DA, Cuthbertson BH, Rowan KM. Is drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?. Critical Care 2011;15(5):R228. x-wiley/crsRef/3118525
69. Sanchez B, Piacentini E, Pradella V, Mignini M, Nava J. Hemodynamic effects of recombinant human activated protein C in patients with septic shock. Journal of Critical Care 2010;25(2):343-7. [PUBMED: 19781904]x-wiley/crsRef/3118527
70. Sanchez-Garcia E, Navarro-Martinez JA, Idrissi A, Paya E, Nicolas N, Mas-Serrano P. Use of drotrecogin alpha in a surgical cohort of intra-abdominal infections patients. European Journal of Anaesthesiology 2011;28:182. x-wiley/crsRef/3118529
71. Shorr AF, Janes JM, Artigas A, Tenhunen J, Wyncoll DL, Mercier E, et al. Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated). Critical Care 2010; Vol. 14, issue 6:R229. [CENTRAL: CN-00802129; PUBMED: 21176144]x-wiley/crsRef/3118531
72. van Doorn KJ, Spapen H, Geers C, Diltoer M, Shabana W. Sepsis-related acute kidney injury: a protective effect of drotrecogin alpha (activated) treatment?. Acta Anaesthesiologica Scandinavica 2008;52(9):1259-64. [MEDLINE: 18823466]x-wiley/crsRef/3118533
73. Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment. Critical Care Medicine 2005;33(10):2266-77. [MEDLINE: 16215381]x-wiley/crsRef/3118535
74. Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde Zwirble W, et al. A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial. Critical Care Medicine 2008;36(1):14-23. [MEDLINE: 18158435]x-wiley/crsRef/3118537
75. Wiedermann CJ, Kaneider NC. A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis. BMC Emergency Medicine 2005;5:1-4. [MEDLINE: 16225672]x-wiley/crsRef/3118539
76. No authors listed. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Critical Care Medicine 1992;20(6):864-74. [MEDLINE: 1597042]
77. Angus DC, Wax RS. Epidemiology of sepsis: An update. Critical Care Medicine 2001;29 Suppl 7:109-16. [MEDLINE: 11445744]
78. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated cost of care. Critical Care Medicine 2001;29(7):1303-10. [MEDLINE: 11445675]
79. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005;365(9453):63-78. [MEDLINE: 15639681]
80. Azevedo LC, Park M, Schettino GP. Novel potential therapies for septic shock. Shock 2008;30 Suppl 1:60-6. [MEDLINE: 18704007]
81. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6. [PUBMED: 21208779]
82. Barnato AE, Alexander SL, Linde-Zwirble WT, Angus DC. Racial variation in the incidence, care, and outcomes of severe sepsis: analysis of population, patient, and hospital characteristics. American Journal of Respiratory and Critical Care Medicine 2008;177(3):279-84. [MEDLINE: 17975201]
83. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003;289(4):454-65. [MEDLINE: 12533125]
84. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. New England Journal Medicine 2001;344(10):699-709. [MEDLINE: 11236773]
85. Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, Sprague S, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. Canadian Medical Association Journal 2004;170(4):477-80. [MEDLINE: 14970094]
86. Bochud PY, Glauser MP, Calandra T, International Sepsis Forum. Antibiotics in sepsis. Intensive Care Medicine 2001;27 Suppl 1:33-48. [MEDLINE: 11307369]
87. Bochud PY, Bonten M, Marchetti O, Calandra T. Antimicrobial therapy for patients with severe sepsis and septic shock: An evidence-based review. Critical Care Medicine 2004;32(11 Suppl):495-512. [MEDLINE: 15542958]
88. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101(6):1644-55. [MEDLINE: 1303622]
89. Boussekey N, Chiche A, Faure K, Devos P, Guery B, D'Escrivan T, et al. A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock. Intensive Care Medicine 2008;34(9):1646-53. [MEDLINE: 18542921]
90. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61(8):763-9. [PUBMED: 18411040]
91. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98. [PUBMED: 18824466]
92. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, et al. Incidence, risk factors and outcomes of severe sepsis and septic shock in adults: A multicenter prospective study in intensive care units. JAMA 1995;274(12):968-74. [MEDLINE: 7674528]
93. Brun-Buisson C. Epidemiology of severe sepsis [Épidémiologie des états septiques graves]. Presse Médicale 2006;35(3 Pt 2):513-20. [MEDLINE: 16550152]
94. Carlet J, Cohen J, Calandra T, Opal SM, Masur H. Sepsis: time to reconsider the concept. Critical Care Medicine 2008;36(3):964-6. [MEDLINE: 18431286]
95. Cheng B, Xie G, Yao S, Wu X, Guo Q, Gu M, et al. Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Critical Care Medicine 2007;35(11):2538-46. [MEDLINE: 17828034]
96. Christiaans SC, Wagener BM, Esmon CT, Pittet JF. Protein C and acute inflammation: a clinical and biological perspective. American Journal of Physiology. Lung Cellular and Molecular Physiology 2013;305(7):L455-66. [PUBMED: 23911436]
97. Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a primer. Critical Care Medicine 2009;37(1):291-304. [MEDLINE: 19050640]
98. Cohen J. Non-antibiotic strategies for sepsis. Clinical Microbiology and Infection 2009;15(4):302-7. [MEDLINE: 19416301]
99. Cohen J, Brun-Buisson C, Torres A, Jorgensen J. Diagnosis of infection in sepsis: An evidence-based review. Critical Care Medicine 2004;32(11):466-94. [MEDLINE: 15542957]
100. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. Trial Sequential Analysis. Copenhagen, Denmark: Copenhagen Trial Unit, Centre for Clinical Intervention Research, 2011.
101. Cunneen J, Cartwright M. The puzzle of sepsis: fitting the pieces of the inflammatory response with treatment. AACN Clinical Issues 2004;15(1):18-44. [MEDLINE: 14767363]
102. Cunnington A, Nadel S. New therapies for sepsis. Current Topics in Medicinal Chemistry 2008;8(7):603-14. [MEDLINE: 18473886]
103. Danai PA, Sinha S, Moss M, Haber MJ, Martin GS. Seasonal variation in the epidemiology of sepsis. Critical Care Medicine 2007;35(2):410-5. [MEDLINE: 17167351]
104. Das UN. Critical advances in septicemia and septic shock. Critical Care 2000;4(5):290-6. [MEDLINE: 11094508]
105. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating non-randomised intervention studies. Health Technology Assessment 2003;7(27):iii-x, 1-173. [PUBMED: 14499048]
106. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Medicine 2008;34(1):17-60. [MEDLINE: 18058085]
107. European Medicines Agency´s Committee for Medicinal Products for Human Use. Drotrecogin alfa (activated) only for use in high risk patients. EMEA's post-authorisation summary of opinion for Xigris, EMEA/138447/2005, 21 April 2005. www.emea.europa.eu/ (accessed 29 November 2010).
108. European Medicines Agency. Xigris (drotrecogin alfa (activated)) to be withdrawn due to lack of efficacy. Press Release 25 October 2011; Vol. EMA/856472/2011 Press Office:1-2.
109. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Seminars in Thrombosis and Hemostasis 2006;32 Suppl 1:49-60. [MEDLINE: 16673266]
110. Food, Drug Administration. FDA Anti-Infective Drugs Advisory Committee12 September 2001: Briefing Document for XIGRIS™ for the Treatment of Severe Sepsis. Eli Lilly and Company. 06 August 2001. Available for public disclosure without redaction. http://www.fda.gov/ohrms/dockets/AC/01/briefing/3797b1_01_Sponsor.pdf (accessed 10 June 2009).
111. Food, Drug Administration. FDA Briefing document: Anti-infective Advisory Committee. Drotrecogin alfa (activated)). [Recombinant human activated protein (rhAPC)]. XIGRIS™ BLA # 125029/0. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1_02_FDAbriefing.pdf (accessed 21 September 2005).
112. Food, Drug Administration. MedWatch - Xigris [drotrecogin alfa (activated)]. www.fda.gov/medwatch/safety/2005/xigris_dearHCP_4-21-05.htm [Posted 01-07-2005] (accessed 21 September 2005).
113. Finfer S, Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, et al. Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Medicine 2008;34(11):1935-47. [MEDLINE: 18839141]
114. Fisher CJ, Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Critical Care Medicine 2000;28 Suppl 9:49-56. [MEDLINE: 11007198]
115. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Critical Care Medicine 2003;31(12):2742-51. [MEDLINE: 14668610]
116. Garnacho-Montero J, Aldabo-Pallas T, Garnacho-Montero C, Cayuela A, Jiménez R, Barroso S, et al. Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis. Critical Care 2006;10(4):R111. [MEDLINE: 16859504]
117. Geroulanos S, Douka ET. Historical perspective of the word "sepsis". Intensive Care Medicine 2006;32(12):2077. [MEDLINE: 17131165]
118. Girbes AR, Beishuizen A, Strack van Schijndel RJ. Pharmacological treatment of sepsis. Fundamental and Clinical Pharmacology 2008;22(4):355-61. [MEDLINE: 18705746]
119. Goldstein B, Giroir B, Randolph A, International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatric Critical Care Medicine 2005;6(1):2-8. [MEDLINE: 15636651]
120. Guidet B, Aegerter P, Gauzit R, Meshaka P, Dreyfuss D, CUB-Réa Study Group. Incidence and impact of organ dysfunctions associated with sepsis. Chest 2005;127(3):942-51. [MEDLINE: 15764780]
121. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011;64(4):395-400. [PUBMED: 21194891]
122. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [PUBMED: 21195583]
123. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407-15. [PUBMED: 21247734]
124. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology 2011;64(12):1311-6. [PUBMED: 21802902]
125. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence--indirectness. Journal of Clinical Epidemiology 2011;64(12):1303-10. [PUBMED: 21802903]
126. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302. [PUBMED: 21803546]
127. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93. [PUBMED: 21839614]
128. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. Journal of Clinical Epidemiology 2011;64(12):1277-82. [PUBMED: 21802904]
129. Healy DP. New and emerging therapies for sepsis. Annals of Pharmacotherapy 2002;36(4):648-54. [MEDLINE: 11918516]
130. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
131. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2009. Available from www.cochrane-handbook.org.
132. Hinds CJ. Treatment of sepsis with activated protein C. BMJ 2001;323(7318):881-2. [MEDLINE: 11668121]
133. Holmes CL, Russell JA, Walley KR. Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy. Chest 2003;124(3):1103-15. [MEDLINE: 12970043]
134. Hotchkiss RS, Opal S. Immunotherapy for sepsis - a new approach against an ancient foe. New England Journal of Medicine 2010;363(1):87-9. [MEDLINE: 20592301]
135. Ianaro A, Tersigni M, D'Acquisto F. New insight in LPS antagonist. Mini Reviews in Medicinal Chemistry 2009;9(3):306-17. [MEDLINE: 19275723]
136. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice1997 CFR & ICH Guidelines. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
137. Ioannidis JP. The art of getting it wrong. Research Synthesis Methods 2010;1(3-4):169-84.
138. Iñigo J, Sendra JM, Díaz R, Bouza C, Sarría-Santamera A. Epidemiology and costs of severe sepsis in Madrid. A hospital discharge study [Epidemiología y costes de la sepsis grave en Madrid.Estudio de altas hospitalarias]. Medicina Intensiva 2006;30(5):197-203. [MEDLINE: 16938192]
139. Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ 2006;333(7572):782-5. [MEDLINE: 17028106]
140. Kalil AC, LaRosa SP. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. The Lancet Infectious Diseases 2012;12(9):678-86. [PUBMED: 22809883]
141. Khan SN, Mermer MJ, Myers E, Sandhu HS. The roles of funding source, clinical trial outcome, and quality of reporting in orthopedic surgery literature. The American Journal of Orthopedic Surgery 2008;37(12):205-12. [MEDLINE: 19212579]
142. Khwannimit B, Bhurayanontachai R. The epidemiology of, and risk factors for, mortality from severe sepsis and septic shock in a tertiary-care university hospital setting. Epidemiology and Infection 2009;137(9):1-9. [MEDLINE: 19192320]
143. King EG, Bauza GJ, Mella JR, Remick DG. Pathophysiologic mechanisms in septic shock. Laboratory Investigation 2013;Epub ahead of print:Sep 23. [PUBMED: 24061288]
144. Kumar A, Mann HJ. Appraisal of four novel approaches to the prevention and treatment of sepsis. American Journal of Health-System Pharmacists 2004;61(8):765-74. [MEDLINE: 15127959]
145. Leon CG, Tory R, Jia J, Sivak O, Wasan KM. Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. Pharmaceutical Research 2008;25(8):1751-61. [MEDLINE: 18493843]
146. Leone M, Textoris J, Michel F, Wiramus S, Martin C. Emerging drugs in sepsis. Expert Opinion on Emerging Drugs 2010;15(1):41-52. [EMBASE: 2010160115; MEDLINE: 20055688]
147. Levi M. The coagulant response in sepsis. Clinics in Chest Medicine 2008;29(45):627-42. [MEDLINE: 18954698]
148. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326(7400):1167-70. [MEDLINE: 12775614]
149. Lexchin JR. Implications of pharmaceutical industry funding on clinical research. Annals of Pharmacotherapy 2005;39(1):194-7. [MEDLINE: 15562137]
150. Mann HJ. Recombinant human activated protein C in severe sepsis. American Journal of Health-System Pharmacy 2002;59 Suppl 1:19-23. [MEDLINE: 11885409]
151. Mann HJ, Short MA, Schlichting DE. Protein C in critical illness. American Journal of Health-System Pharmacy 2009;66(12):1089-96. [MEDLINE: 19498123]
152. Marshall JC, Maier RV, Jimenez M, Dellinger EP. Source control in the management of severe sepsis and septic shock: an evidence-based review. Critical Care Medicine 2004;32 Suppl 11:513-26. [MEDLINE: 15542959]
153. Marshall JC. Sepsis: Rethinking the approach to clinical research. Journal of Leukocyte Biology 2008;83(3):471-82. [MEDLINE: 18171697]
154. Matsuda N, Hattori Y. Vascular biology in sepsis: pathophysiological and therapeutic significance of vascular dysfunction. Journal of Smooth Muscle Research 2007;43(4):117-37. [MEDLINE: 17928746]
155. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine --selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003;326(7400):1171-3. [MEDLINE: 12775615]
156. Mitka M. Drug for severe sepsis is withdrawn from market, fails to reduce mortality. JAMA 2011; Vol. 306, issue 22:2439-40. [PUBMED: 22166598]
157. Moine P. Potential benefits of non-anti-infective treatments of septic shock: a critical analysis of literature. Annales Francaises D'Anesthesie Et De Reanimation 2007;26(4):370-5. [MEDLINE: 17395418]
158. Parrish WR, Gallowitsch-Puerta M, Czura CJ, Tracey KJ. Experimental therapeutic strategies for severe sepsis: mediators and mechanisms. Annals of the New York Academy of Sciences 2008;1144:210-36. [MEDLINE: 19076379]
159. Paul M. Is there a treatment for sepsis other than antibiotics?. Clinical Microbiology and Infection 2009;15(4):297. [MEDLINE: 19416299]
160. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, et al. Hydroxyethyl starch 130/0.4 versus Ringer's acetate in severe sepsis. The New England journal of medicine 2012;June 27:[Epub ahead of print]. [PUBMED: 22738085]
161. Porta M. A Dictionary of Epidemiology. Fifth. New York: Oxford University Press, 2008.
162. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995;273(2):117-23. [MEDLINE: 7799491]
163. Remick DG. Pathophysiology of sepsis. The American Journal of Pathology 2007;17(5):1435-44. [MEDLINE: 17456750]
164. The Nordic Cochrane Centre: The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2011.
165. Rhodes A, Bennett ED. Early goal-directed therapy: An evidence-based review. Critical Care Medicine 2004;32 Suppl 11:448-50. [MEDLINE: 15542954]
166. Rigato O, Silva E, Salomao R. Pathogenesis-oriented targets for adjunctive therapy. Endocrine Metabolic & Immune Disorders-Drug Targets 2006;6(2):193-200. [MEDLINE: 16787294]
167. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nature Reviews. Inmmunology 2008;8(10):776-87. [MEDLINE: 18802444]
168. Sandrock CE, Albertson TE. Controversies in the treatment of sepsis. Seminars in Respiratory and Critical Care Medicine 2010;31(1):66-78. [EMBASE: 2010112081; MEDLINE: 20101549]
169. Schuerholz T, Marx G. Management of sepsis. Minerva Anestesiologica 2008;74(5):181-95. [MEDLINE: 18414361]
170. Shorr AF, Bernard GR, Dhainaut JF, Russell JR, Macias WL, Nelson DR, et al. Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Critical Care 2006;10(3):R92. [MEDLINE: 16780598]
171. Shorr AF, Nelson DR, Wyncoll DLA, Reinhart K, Brunkhorst F, Vail G, et al. Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated). Critical Care 2008;12(2):R45. [MEDLINE: 18394162]
172. Sibila O, Agustí C, Torres A. Corticosteroids in severe pneumonia. The European Respiratory Journal 2008;32(2):259-64. [MEDLINE: 18669784]
173. Sipahi T, Pocan H, Akar N. Effect of various genetic polymorphisms on the incidence and outcome of severe sepsis. Clinical and Applied Thrombosis and Hemostasis 2006;12(1):47-54. [MEDLINE: 16444434]
174. Sismondo S. How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Social Science & Medicine 2008;66(9):1909-14. [MEDLINE: 18299169]
175. Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemporary Clinical Trials 2008;29(2):109-13. [MEDLINE: 17919992]
176. Sriskandan S, Altmann DM. The immunology of sepsis. The Journal of Pathology 2008;214(2):211-23. [MEDLINE: 18161754]
177. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. International Journal of Epidemiology 2009;38(1):276-86. [PUBMED: 18824467]
178. Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66. [PUBMED: 20865104]
179. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). http://ctu.dk/tsa/files/tsa_manual.pdf (accessed 30 April 2012). 2011.
180. Treacher DF, Alun Brown K. The basic science of sepsis. Surgery 2009;27(11):465-9. [EMBASE: 2009641439]
181. Vincent JL, Abraham E, Annane D, Bernard G, Rivers E, Van den Berghe G. Reducing mortality in sepsis: new directions. Critical Care 2002;6(3 Suppl):1-18. [MEDLINE: 12720570]
182. Vincent JL. Evidence-based medicine in the ICU: important advances and limitations. Chest 2004;126(2):592-600. [MEDLINE: 15302748]
183. Vincent JL, De Backer D. Circulatory shock. New England Journal of Medicine 2013;369(18):1726-34. [PUBMED: 24171518]
184. Wang H, Ward MF, Sama AE. Novel HMGB1-Inhibiting therapeutic agents for experimental sepsis. Shock 2009;32(4):348-57. [MEDLINE: 19333143]
185. Wang H, Zhu S, Zhou R, Li W Sama AE. Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Reviews in Molecular Medicine 2008;10(32):1-20.
186. Wesche-Soldato DE, Swan RZ, Chung CS, Ayala A. The apoptotic pathway as a therapeutic target in sepsis. Current Drug Targets 2007;8(4):493-500. [MEDLINE: 17430119]
187. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75. [PUBMED: 18083463]
188. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86. [PUBMED: 20042080]
189. Wittebole X, Collienne C, Castanares-Zapatero D, Laterre PF. Adjunctive therapies for severe sepsis. International Journal of Antimicrobial Agents 2008;32 Suppl 1:34-8. [MEDLINE: 18715758]
190. Yan SB, Dhainaut JF. Activated protein C versus protein C in severe sepsis. Critical Care Medicine 2001;29(7 Suppl):69-74. [MEDLINE: 11445737]
191. Zavala D, Martí-Carvajal A, Peña-Martí G, Comunián G. Data extraction sheet to help manage the characteristics of included studies in Cochrane reviews. Valencia: Universidad de Carabobo, 2006.
192. Marti-Carvajal AJ, Sola I, Gluud C, Lathyris D, Cardona AF. Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD007175.pub3]
193. Martí-Carvajal A, Salanti G, Cardona AF. Human recombinant activated protein C for severe sepsis. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD004388.pub2]
194. Martí-Carvajal A, Salanti G, Cardona AF. Human recombinant activated protein C for severe sepsis. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD004388.pub3]
195. Martí-Carvajal Arturo J, Solà I, Lathyris D, Cardona AF. Human recombinant activated protein C for severe sepsis. Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/14651858.CD004388.pub4; CD004388]
196. Martí-Carvajal AJ, Solà I, Lathyris D, Cardona AF. Human recombinant activated protein C for severe sepsis. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD004388.pub5]